Compare TTRX & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTRX | MSLE |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | 2 | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 146.9M |
| IPO Year | N/A | N/A |
| Metric | TTRX | MSLE |
|---|---|---|
| Price | $5.99 | $5.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 58.2K | 27.5K |
| Earning Date | 05-31-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $5.50 |
| 52 Week High | $6.75 | $13.39 |
| Indicator | TTRX | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 36.50 |
| Support Level | $4.70 | N/A |
| Resistance Level | $6.68 | $8.59 |
| Average True Range (ATR) | 0.56 | 0.39 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 53.36 | 0.00 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.